

Perimeter Medical Imaging AI to Participate in Panel Discussion “Innovations in Breast Cancer Detection, Surgery and Treatment” at the Lytham Partners Summer 2021 Investor Conference

Panel discussion scheduled for 5:00pm ET on Tuesday, June 15, 2021

TORONTO--(BUSINESS WIRE)-- Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF)(FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced that the Company's Chief Executive Officer, Jeremy Sobotta, will participate in a panel at the Lytham Partners Summer 2021 Investor Conference titled “Innovations in Breast Cancer Detection, Surgery and Treatment.”

- The virtual panel will be held on Tuesday, June 15, 2021, at 5:00pm ET. To access the panel, please visit: <https://wsw.com/webcast/lytham/panel5/2194955>.

Management will also be participating in virtual one-on-one meetings throughout the event, which runs from June 14, 2021 through June 16, 2021. To arrange a meeting, please contact Lytham Partners at 1x1@lythampartners.com or register at www.lythampartners.com/summer2021invreg.

About Perimeter S-Series OCT

Cleared by the U.S. FDA, Perimeter S-Series Optical Coherence Tomography (OCT) is a novel medical imaging system that provides clinicians with cross-sectional, real-time margin visualization (1-2 mm below the surface) of an excised tissue specimen. Giving physicians the ability to visualize microscopic tissue structures “real time” in the operating room has the potential to result in better long-term outcomes for patients and lower costs to the healthcare system.

About Perimeter B-Series OCT with ImgAssist AI

Perimeter is advancing the development of its proprietary, next-gen “ImgAssist” artificial intelligence technology under its ATLAS AI project, which is made possible, in part, by a US\$7.4 million grant awarded by the Cancer Prevention and Research Institute of Texas (CPRIT). The U.S. FDA granted Breakthrough Device Designation for Perimeter B-Series OCT coupled with ImgAssist AI, and Perimeter has plans to initiate a randomized, multi-site, pivotal study to evaluate it against the current standard of care and assess the impact on re-operation rates for patients undergoing breast conservation surgery.

About Perimeter Medical Imaging AI, Inc.

With headquarters in Toronto, Canada and Dallas, Texas, [Perimeter Medical Imaging AI](#) (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company that is driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month, underscoring the company's dedication to helping surgeons, radiologists, and pathologists use Perimeter's imaging technology and AI in the fight against breast cancer, which is estimated to [account for 30%](#) of all female cancer diagnoses this year.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20210611005040/en/>

Company Contact:

Shushu Feng

Perimeter Medical Imaging AI, Inc.

(647) 360-0302

media@perimetermed.com

www.perimetermed.com

Investor Contact:

Ben Shamsian or Joe Dorame

Lytham Partners, LLC

Direct: 646-829-9701

Main: 602 889 9700

PINK@lythampartners.com

www.lythampartners.com

Source: Perimeter Medical Imaging AI, Inc.